A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Conditions: Breast Cancer; Colorectal Cancer; Ovarian Cancer; Non-Small Cell Lung Cancer; Acral Lentiginous Melanoma; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; DMMR Colorectal Cancer; MSI-H Colorectal Cancer; Melanoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer
Interventions: Biological: ATRC-101; Biological: Pembrolizumab; Drug: Pegylated liposomal doxorubicin (PLD)
Sponsor: Atreca, Inc.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.